Aditxt Inc Stock Price, News & Analysis

Evofem Biosciences (OTCPK: EVFM) presented promising study results for SOLOSEC (secnidazole) in treating recurrent bacterial vaginosis (BV) at the 2025 ACOG Annual Meeting. The clinical study of 24 women showed that once-weekly dosing of SOLOSEC 2g oral granules demonstrated efficacy comparable or potentially superior to current CDC-recommended suppressive treatments. BV affects approximately 21 million U.S. women, with up to 50% experiencing recurrence within six months of treatment. The BV treatment market is projected to reach $1.0 billion in the U.S. by 2033. While SOLOSEC is currently approved for BV treatment in women aged 12 and older, its use in recurrent BV remains investigational. The simplified once-weekly oral dosing regimen could potentially improve treatment adherence compared to more complex existing protocols.

Aditxt (ADTX) has appointed Evofem Biosciences CEO Saundra Pelletier to its Board of Directors. Pelletier brings over three decades of pharmaceutical industry experience, specializing in women's health. During her 10-year leadership at Evofem, she successfully led the company's public market transition and oversaw the approval of PHEXXI, a hormone-free contraceptive gel, and SOLOSEC, an antibiotic for bacterial infections. Her appointment aligns with Aditxt's strategy to expand into women's health monitoring, prevention, and treatment. Pelletier's extensive background includes roles at Woman Care Global and G.D. Searle, and she currently serves on multiple boards including Windtree Therapeutics.

Aditxt (NASDAQ: ADTX) announced its upcoming Weekly Update event on June 6, 2025, featuring CEO Amro Albanna and three prominent healthcare leaders. The virtual event will include Dr. Friedrich Kapp, co-CEO of Adimune, discussing ADI-100, an antigen-specific gene therapy for autoimmune diseases; Chris Mitton, president of Pearsanta, presenting on Mitomic diagnostic tests for endometriosis and prostate cancer; and Saundra Pelletier, CEO of Evofem Biosciences, sharing insights on women's health. The event will take place at 11:30 a.m. ET via Zoom, highlighting developments in immune therapy, disease detection, and women's healthcare innovations.

Aditxt (NASDAQ: ADTX) has announced the termination of its Arrangement Agreement with Appili Therapeutics, which was originally announced in April 2024. The termination, effective May 31, 2025, will eliminate approximately $16 million in closing obligations. Despite multiple amendments to extend key milestones and accommodate changing circumstances, Aditxt determined that proceeding with the agreement was no longer strategically aligned with the company's interests. CEO Amro Albanna expressed appreciation for Appili's team while confirming this decision as the best course of action for Aditxt and its stockholders.

Aditxt (NASDAQ: ADTX) has announced that its Chief Innovation Officer, Dr. Shahrokh Shabahang, and Adimune's Co-CEO, Dr. Friedrich Kapp, will participate in the company's Weekly Update today at 11:30 a.m. ET. The virtual event will focus on discussing recent developments of ADI-100™, which is the lead therapeutic candidate of Adimune, Aditxt's wholly owned subsidiary. The event will be held virtually via Zoom, and interested participants can register through the provided link.

Aditxt (NASDAQ: ADTX) has announced that Dr. Charles Howe from Mayo Clinic's Neuroimmunology Department will join their Weekly Update on May 2, 2025. Dr. Howe, who chairs the Division of Experimental Neurology and directs Research at Mayo Clinic's Center for Multiple Sclerosis and Autoimmune Neurology, will discuss findings from a recent preclinical study of ADI-100™, the lead therapeutic candidate from Aditxt's subsidiary Adimune™.

The virtual event will also feature Dr. Shahrokh Shabahang, Aditxt's Chief Innovation Officer, and Dr. Friedrich Kapp, Adimune's Co-CEO. The update is scheduled for 11:30 a.m. ET via Zoom.

Aditxt (NASDAQ: ADTX) announced that its subsidiary Pearsanta has received IRB approval to begin a clinical study for the Mitomic® Endometriosis Test (MET), a blood-based diagnostic tool for endometriosis detection. The study will evaluate MET's performance against laparoscopic diagnosis, enrolling up to 1,000 participants starting May 2025.

The study aims to assess MET's sensitivity and specificity across disease subtypes, explore correlations between test results and symptoms, and establish a biobank for future research. MET utilizes mitochondrial DNA biomarkers to detect disease signatures through a simple blood draw, potentially offering a non-invasive alternative to surgical diagnosis.

Endometriosis affects 1 in 10 women globally, with diagnosis typically taking 7-10 years due to current diagnostic limitations. The study results will support MET's launch as a Laboratory Developed Test at Pearsanta's CLIA/CAP-certified laboratory in Richmond, Virginia.

Aditxt (NASDAQ: ADTX) announced positive results from Mayo Clinic pre-clinical studies for its subsidiary Adimune's lead therapeutic candidate ADI-100. The study, led by Mayo Clinic's neuroimmunology team, validated that ADI-100 induces immune tolerance to glutamic acid decarboxylase (GAD), a key autoantigen in multiple autoimmune conditions.

Key findings include:

• Confirmation of ADI-100's safety profile with no increased T cell reactivity to GAD
• Dendritic cells treated with ADI-100 showed increased tolerogenic markers
• ADI-100-induced tolerogenic dendritic cells reduced activation of T cells from GAD-sensitive patients

The findings were presented at the American Academy of Neurology Annual Meeting. With pre-clinical efficacy and safety studies complete and GMP manufacturing finalized, Adimune plans regulatory submissions for the second half of 2025, targeting subsequent first-in-human clinical trials.

Aditxt (NASDAQ: ADTX), a social innovation platform focused on health innovations, has announced its Weekly Update event scheduled for today at 11:30 a.m. ET. The virtual meeting will address several key developments, including the company's recent achievement of regaining compliance with Nasdaq's minimum bid price requirement, ensuring continued listing on the Nasdaq Capital Market.

The event will also provide updates on the company's operating subsidiaries and discuss ongoing strategic transactions. The meeting will be held virtually via Zoom, with registration required for attendance.